Evidence map›Paper›PMID 37498346›Full record

Observational studyClinical and experimental nephrology2023

Angiotensin II receptor blockers and bone fracture in chronic kidney disease patients: the Fukuoka kidney disease Registry Study.

Tomoya Shukuri, Kentaro Nakai, Shigeru Tanaka, Shunsuke Yamada, Masanori Tokumoto, Kazuhiko Tsuruya, Toshiaki Nakano, Takanari Kitazono

Abstract readObservational StudyMulticenter Study
PubMed Publisher
In one paragraph

Observational study in Clinical and experimental nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Tomoya ShukuriDeparture of Nephrology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan.
Kentaro NakaiDeparture of Nephrology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan.
Shigeru TanakaDepartment of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higasi-Ku, Fukuoka, Japan.
Shunsuke YamadaDepartment of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higasi-Ku, Fukuoka, Japan.
Masanori TokumotoDeparture of Nephrology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan.
Kazuhiko TsuruyaDepartment of Nephrology, Nara Medical University, Kashihara, Japan.
Toshiaki NakanoDepartment of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higasi-Ku, Fukuoka, Japan. nakano.toshiaki.455@m.kyushu-u.ac.jp.ORCID http://orcid.org/0000-0001-9235-5615
Takanari KitazonoDepartment of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higasi-Ku, Fukuoka, Japan.
Kyushu University · JPJapanese Red Cross Fukuoka Hospital · JPNara Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAngiotensin II receptor blockers (ARBs) reportedly reduce the risk of developing bone fractures; however, this association remains unclear among patients with chronic kidney disease (CKD).

methodsThis was a cross-sectional study of 3380 CKD patients enrolled in the Fukuoka Kidney disease Registry Study, a multicenter prospective observational cohort study of non-dialysis-dependent CKD patients. The patients were divided into two groups, those taking ARBs and those who were not. Logistic regression models were used to examine the association between ARBs and bone fracture.

resultsApproximately 67.0% of the participants were on ARBs, and 6.3% had a history of bone fracture. The history of bone fracture was significantly lower in patients with prescribed ARB and remained significant even after multivariable adjustment (odds ratio, 0.68; 95% confidence interval, 0.51-0.93). Other antihypertensive drugs, such as thiazide diuretics, which were reportedly helpful in preventing fractures, did not alter the bone fracture history and did not change among ARB users and non-users.

conclusionsThe present study showed that administering ARB was significantly associated with a lower frequency of bone fracture history.

Indexed as

Fractures, BoneRenal Insufficiency, ChronicAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsCross-Sectional StudiesHumansProspective StudiesRegistriesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor Antagonistsangiotensin II receptor blockersBone fractureChronic kidney diseaseFukuoka Kidney disease Registry Study

Identifiers

PMID37498346
OpenAlexW4385295850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.